Financhill
Sell
44

GLTO Quote, Financials, Valuation and Earnings

Last price:
$3.09
Seasonality move :
-3.52%
Day range:
$3.05 - $3.21
52-week range:
$2.01 - $16.07
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.33x
Volume:
12.3K
Avg. volume:
70.3K
1-year change:
-79.87%
Market cap:
$4.1M
Revenue:
--
EPS (TTM):
-$15.54

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
GLTO
Galecto
-- -$2.82 -- -51.46% $6.00
ASND
Ascendis Pharma AS
$107.9M -$1.71 294.46% -21.49% $221.46
EVAX
Evaxion AS
$60K -$0.71 -100% -90.33% $13.25
GMAB
Genmab AS
$759.6M $0.23 16.33% 7.82% $29.31
IOBT
IO Biotech
-- -$0.23 -- -3.23% $9.50
NVO
Novo Nordisk AS
$11.9B $0.92 19.3% 36.74% $89.76
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
GLTO
Galecto
$3.07 $6.00 $4.1M -- $0.00 0% --
ASND
Ascendis Pharma AS
$162.84 $221.46 $9.9B -- $0.00 0% 24.25x
EVAX
Evaxion AS
$2.46 $13.25 $15.5M -- $0.00 0% 1.63x
GMAB
Genmab AS
$20.95 $29.31 $12.9B 12.46x $0.00 0% 4.39x
IOBT
IO Biotech
$1.42 $9.50 $93.6M -- $0.00 0% --
NVO
Novo Nordisk AS
$71.50 $89.76 $317.7B 21.18x $1.14 2.32% 7.31x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
GLTO
Galecto
-- 1.269 -- --
ASND
Ascendis Pharma AS
128.87% 0.179 9.75% 0.67x
EVAX
Evaxion AS
-- -0.376 -- 2.80x
GMAB
Genmab AS
-- 0.045 -- 5.32x
IOBT
IO Biotech
-- -3.128 -- --
NVO
Novo Nordisk AS
46.15% 1.792 5.59% 0.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
GLTO
Galecto
-- -$2.6M -- -- -- -$2.4M
ASND
Ascendis Pharma AS
$87.8M -$106M -59.13% -880.05% -48.32% -$15.8M
EVAX
Evaxion AS
-- -$3.9M -238.97% -- -54.59% --
GMAB
Genmab AS
$673M $188M 22.23% 22.23% 34.83% $257M
IOBT
IO Biotech
-- -$22.6M -- -- -- -$23.1M
NVO
Novo Nordisk AS
$9.2B $5.5B 53.78% 84.88% 54.06% $1.4B

Galecto vs. Competitors

  • Which has Higher Returns GLTO or ASND?

    Ascendis Pharma AS has a net margin of -- compared to Galecto's net margin of -93.73%. Galecto's return on equity of -- beat Ascendis Pharma AS's return on equity of -880.05%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    ASND
    Ascendis Pharma AS
    82.65% -$1.66 $711.6M
  • What do Analysts Say About GLTO or ASND?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 95.44%. On the other hand Ascendis Pharma AS has an analysts' consensus of $221.46 which suggests that it could grow by 36%. Given that Galecto has higher upside potential than Ascendis Pharma AS, analysts believe Galecto is more attractive than Ascendis Pharma AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    ASND
    Ascendis Pharma AS
    12 0 0
  • Is GLTO or ASND More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ascendis Pharma AS has a beta of 0.407, suggesting its less volatile than the S&P 500 by 59.314%.

  • Which is a Better Dividend Stock GLTO or ASND?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Ascendis Pharma AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or ASND?

    Galecto quarterly revenues are --, which are smaller than Ascendis Pharma AS quarterly revenues of $106.2M. Galecto's net income of -$2.5M is higher than Ascendis Pharma AS's net income of -$99.6M. Notably, Galecto's price-to-earnings ratio is -- while Ascendis Pharma AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 24.25x for Ascendis Pharma AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    ASND
    Ascendis Pharma AS
    24.25x -- $106.2M -$99.6M
  • Which has Higher Returns GLTO or EVAX?

    Evaxion AS has a net margin of -- compared to Galecto's net margin of -64.14%. Galecto's return on equity of -- beat Evaxion AS's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    EVAX
    Evaxion AS
    -- -$0.50 $74K
  • What do Analysts Say About GLTO or EVAX?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 95.44%. On the other hand Evaxion AS has an analysts' consensus of $13.25 which suggests that it could grow by 438.62%. Given that Evaxion AS has higher upside potential than Galecto, analysts believe Evaxion AS is more attractive than Galecto.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    EVAX
    Evaxion AS
    1 0 0
  • Is GLTO or EVAX More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Evaxion AS has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLTO or EVAX?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Evaxion AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Evaxion AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or EVAX?

    Galecto quarterly revenues are --, which are smaller than Evaxion AS quarterly revenues of $3M. Galecto's net income of -$2.5M is lower than Evaxion AS's net income of -$1.6M. Notably, Galecto's price-to-earnings ratio is -- while Evaxion AS's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 1.63x for Evaxion AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    EVAX
    Evaxion AS
    1.63x -- $3M -$1.6M
  • Which has Higher Returns GLTO or GMAB?

    Genmab AS has a net margin of -- compared to Galecto's net margin of 27.27%. Galecto's return on equity of -- beat Genmab AS's return on equity of 22.23%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    GMAB
    Genmab AS
    94.13% $0.31 $5.3B
  • What do Analysts Say About GLTO or GMAB?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 95.44%. On the other hand Genmab AS has an analysts' consensus of $29.31 which suggests that it could grow by 39.92%. Given that Galecto has higher upside potential than Genmab AS, analysts believe Galecto is more attractive than Genmab AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    GMAB
    Genmab AS
    4 4 0
  • Is GLTO or GMAB More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genmab AS has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.676%.

  • Which is a Better Dividend Stock GLTO or GMAB?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genmab AS offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. Genmab AS pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or GMAB?

    Galecto quarterly revenues are --, which are smaller than Genmab AS quarterly revenues of $715M. Galecto's net income of -$2.5M is lower than Genmab AS's net income of $195M. Notably, Galecto's price-to-earnings ratio is -- while Genmab AS's PE ratio is 12.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 4.39x for Genmab AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    GMAB
    Genmab AS
    4.39x 12.46x $715M $195M
  • Which has Higher Returns GLTO or IOBT?

    IO Biotech has a net margin of -- compared to Galecto's net margin of --. Galecto's return on equity of -- beat IO Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    IOBT
    IO Biotech
    -- -$0.34 --
  • What do Analysts Say About GLTO or IOBT?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 95.44%. On the other hand IO Biotech has an analysts' consensus of $9.50 which suggests that it could grow by 569.01%. Given that IO Biotech has higher upside potential than Galecto, analysts believe IO Biotech is more attractive than Galecto.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    IOBT
    IO Biotech
    2 0 0
  • Is GLTO or IOBT More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IO Biotech has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock GLTO or IOBT?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IO Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Galecto pays -- of its earnings as a dividend. IO Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios GLTO or IOBT?

    Galecto quarterly revenues are --, which are smaller than IO Biotech quarterly revenues of --. Galecto's net income of -$2.5M is higher than IO Biotech's net income of -$22.4M. Notably, Galecto's price-to-earnings ratio is -- while IO Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus -- for IO Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    IOBT
    IO Biotech
    -- -- -- -$22.4M
  • Which has Higher Returns GLTO or NVO?

    Novo Nordisk AS has a net margin of -- compared to Galecto's net margin of 37.18%. Galecto's return on equity of -- beat Novo Nordisk AS's return on equity of 84.88%.

    Company Gross Margin Earnings Per Share Invested Capital
    GLTO
    Galecto
    -- -$1.92 --
    NVO
    Novo Nordisk AS
    83.49% $0.92 $37.3B
  • What do Analysts Say About GLTO or NVO?

    Galecto has a consensus price target of $6.00, signalling upside risk potential of 95.44%. On the other hand Novo Nordisk AS has an analysts' consensus of $89.76 which suggests that it could grow by 25.54%. Given that Galecto has higher upside potential than Novo Nordisk AS, analysts believe Galecto is more attractive than Novo Nordisk AS.

    Company Buy Ratings Hold Ratings Sell Ratings
    GLTO
    Galecto
    0 1 0
    NVO
    Novo Nordisk AS
    4 4 1
  • Is GLTO or NVO More Risky?

    Galecto has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Novo Nordisk AS has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.706%.

  • Which is a Better Dividend Stock GLTO or NVO?

    Galecto has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk AS offers a yield of 2.32% to investors and pays a quarterly dividend of $1.14 per share. Galecto pays -- of its earnings as a dividend. Novo Nordisk AS pays out 43.71% of its earnings as a dividend. Novo Nordisk AS's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios GLTO or NVO?

    Galecto quarterly revenues are --, which are smaller than Novo Nordisk AS quarterly revenues of $11B. Galecto's net income of -$2.5M is lower than Novo Nordisk AS's net income of $4.1B. Notably, Galecto's price-to-earnings ratio is -- while Novo Nordisk AS's PE ratio is 21.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Galecto is -- versus 7.31x for Novo Nordisk AS. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    GLTO
    Galecto
    -- -- -- -$2.5M
    NVO
    Novo Nordisk AS
    7.31x 21.18x $11B $4.1B

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for May 31

Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Sell
42
AMBA alert for May 31

Ambarella [AMBA] is down 15.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock